LONDONÂ and NEW YORK
 , May 12, 2021 /PRNewswire/  Huma Therapeutics Limited today announces the completion of its latest funding round with financing of approximately $130 million. The investment will scale Huma s modular platform which can power digital hospitals at home nationally, and support the pharmaceutical and research industries to run the largest ever decentralized clinical trials. Huma s platform combines predictive algorithms, digital biomarkers and real-world data to advance proactive care and research.
Leaps by Bayer and Hitachi Ventures led the Series C funding round, which also saw new strategic and financial investors become shareholders. Samsung Next, Sony Innovation Fund by IGV , Unilever Ventures and HAT Technology & Innovation Fund by HAT, as well as individuals Nikesh Arora (former president of SoftBank) and Michael Diekmann (Chairman of Allianz) are also new shareholders.
Huma, which uses AI and biomarkers to monitor patients and for medical research, raises $130M
While much of the world eagerly watches to see if the vaccination rollout helps curb and eventually stamp out Covid-19, one of the companies that has been helping to manage the spread of the virus is announcing a big round of funding on the heels for strong demand for its technology.
Huma, which combines data from biomarkers with predictive algorithms both to help monitor patients, and uses the same technology to help researchers and pharmaceutical companies run clinical trials, has closed an equity round of $130 million, a Series C that the company can extend to $200 million by way of a $70 million debt line if it chooses.
Huma raises $130 million to finance its digital health platform
5 hours ago
Huma Therapeutics Limited thas raised approximately $130 million to scale its modular platform which can power digital ‘hospitals at home’ nationally, and support the pharmaceutical and research industries to run the largest ever decentralised clinical trials. Huma’s platform combines predictive algorithms, digital biomarkers and real-world data to advance proactive care and research.
Leaps by Bayer and Hitachi Ventures led the Series C funding round, which also saw new strategic and financial investors become shareholders. Samsung Next, Sony Innovation Fund by IGV, Unilever Ventures and HAT Technology & Innovation Fund by HAT, as well as individuals Nikesh Arora (former president of SoftBank) and Michael Diekmann (Chairman of Allianz) are also new shareholders.
Samsung, Sony, Hitachi invest in UK healthtech firm Huma
By IANS |
Published on
Wed, May 12 2021 10:48 IST |
14 Views
Dollar.. Image Source: IANS News
London, May 12 : Samsung, Sony and Hitachi have invested in UK heathtech company Huma Therapeutics Limited in its latest Series C funding round with financing of approximately $130 million, the company said on Wednesday.
Leaps by Bayer and Hitachi Ventures led the Series C funding round, which also saw strategic and financial investors like Samsung Next, Sony Innovation Fund by IGV, Unilever Ventures and HAT Technology & Innovation Fund by HAT, as well as individuals Nikesh Arora (former president of SoftBank) and Michael Diekmann (Chairman of Allianz).